(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Sound Maturing: Wellbeing Tips for Each Life Stage - 2ONE returns to Red Sea with new service
- 3Instructions to Decide the Best SUV Size for Seniors
- 4Air Canada CEO To Resign After Backlash—Here’s Why Communication Skills Is Now A Leadership Requirement
- 5Israeli lawmakers pass bill reviving death penalty for terrorists
- Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
- The Manual for Electric Vehicles that will be hot dealers in 2023
- CDC clarifies stance on vaccines and autism, stating no evidence supports the link
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- Manual for Mountain Objections on the planet
- Five held on suspicion of planning attack on German Christmas market
- Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- 9 African migrants died in freezing temperatures near Morocco-Algeria border
- Israel explores creation of int'l force with Greece, Cyprus to deter Turkey
